Supernus Pharmaceuticals, Inc. v. Lupin Limited et al
| Supernus Pharmaceuticals, Inc. |
| Lupin Limited, Lupin Atlantis Holdings S.A., Nanomi B.V., Lupin Inc. and Lupin Pharmaceuticals, Inc. |
| 1:2021cv01293 |
| September 10, 2021 |
| US District Court for the District of Delaware |
| Maryellen Noreika |
| Patent - Abbreviated New Drug Application(ANDA) |
| 28 U.S.C. ยง 1338 |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on April 5, 2023. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Filing 7 NOTICE of Waiver of Summons by Supernus Pharmaceuticals, Inc. (Attachments: #1 Exhibit A)(DiGiovanni, Francis) |
| Pro Hac Vice Attorney Edgar H. Haug, Richard F. Kurz, and Nicholas F. Giove for Supernus Pharmaceuticals, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mal) |
SO ORDERED re #6 MOTION for Pro Hac Vice Appearance of Attorney Edgar H. Haug, Nicholas F. Giove, Richard F. Kurz filed by Supernus Pharmaceuticals, Inc. ORDERED by Judge Maryellen Noreika on 9/16/2021. (dlw)
|
| Case Assigned to Judge Maryellen Noreika. Please include the initials of the Judge (MN) after the case number on all documents filed. (rjb) |
| Filing 6 MOTION for Pro Hac Vice Appearance of Attorney Edgar H. Haug, Nicholas F. Giove, Richard F. Kurz - filed by Supernus Pharmaceuticals, Inc.. (DiGiovanni, Francis) |
| Filing 5 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent The Vanguard Group, Inc., and Corporate Parent BlackRock Institutional Trust Company for Supernus Pharmaceuticals, Inc. filed by Supernus Pharmaceuticals, Inc. (srs) |
| Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,298,576 ; 8,298,580 ; 8,663,683 ; 8,877,248 ; 8,889,191 ; 8,992,989 ; 9,549,940 ; 9,555,004 ; 9,622,983 ; 10,314,790 . (srs) |
| Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 07/30/2021. Date of Expiration of Patent: 11/16/2027 for all patents except 8,298,576 4/4/2028.Thirty Month Stay Deadline: 1/30/2024. (srs) |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (srs) |
| Filing 1 COMPLAINT filed against Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., and Nanomi B.V. - Magistrate Consent Notice to Pltf. ( Filing fee $ 402, receipt number ADEDC-3696566.) - filed by Supernus Pharmaceuticals, Inc. (Attachments: #1 Exhibit A, #2 Exhibit B, #3 Exhibit C, #4 Exhibit D, #5 Exhibit E, #6 Exhibit F, #7 Exhibit G, #8 Exhibit H, #9 Exhibit I, #10 Exhibit, #11 Civil Cover Sheet)(srs) |
| No Summons Issued. (srs) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
